A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The
primary purpose of this trial is to evaluate the safety and tolerability, and
pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.